These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31396727)

  • 1. Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin.
    Han S; Kim YH; Choi HY; Kim MJ; Kim WJ; Park H; Bae KS; Lim HS
    Pharm Res; 2019 Aug; 36(10):146. PubMed ID: 31396727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.
    Zhang DM; Wang K; Zhao X; Li YF; Zheng QS; Wang ZN; Cui YM
    Acta Pharmacol Sin; 2012 Nov; 33(11):1387-94. PubMed ID: 22659624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers.
    Gou ZP; Song ZH; Chen XG; Hu XC; Wang Y; Fan K; Cai YM; Zheng L
    CNS Drugs; 2019 Jun; 33(6):605-614. PubMed ID: 31093952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects.
    Zhang D; Wang Z; Zhao X; Lu W; Gu J; Cui Y
    Biol Pharm Bull; 2011; 34(12):1841-8. PubMed ID: 22130240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
    Fox I; Dawson A; Loynds P; Eisner J; Findlen K; Levin E; Hanson D; Mant T; Wagner J; Maraganore J
    Thromb Haemost; 1993 Feb; 69(2):157-63. PubMed ID: 8456428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Errors-in-variables in joint population pharmacokinetic/pharmacodynamic modeling.
    Bennett J; Wakefield J
    Biometrics; 2001 Sep; 57(3):803-12. PubMed ID: 11550931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
    Robson R; White H; Aylward P; Frampton C
    Clin Pharmacol Ther; 2002 Jun; 71(6):433-9. PubMed ID: 12087346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric catheterization laboratory anticoagulation with bivalirudin.
    Forbes TJ; Hijazi ZM; Young G; Ringewald JM; Aquino PM; Vincent RN; Qureshi AM; Rome JJ; Rhodes JF; Jones TK; Moskowitz WB; Holzer RJ; Zamora R
    Catheter Cardiovasc Interv; 2011 Apr; 77(5):671-9. PubMed ID: 21433272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bivalirudin: a direct thrombin inhibitor in percutaneous coronary interventions].
    Hansen PR
    Ugeskr Laeger; 2006 Sep; 168(38):3207-9. PubMed ID: 17026893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
    Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
    BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of bivalirudin in patients with renal impairment.
    Robson R
    J Invasive Cardiol; 2000 Dec; 12 Suppl F():33F-6. PubMed ID: 11156732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative in vitro study of anticoagulant activity of RA36 DNA aptamer in human, rabbit, and rat blood plasma].
    Savchik EIu; Kalinina TB; Drozd NN; Makarov VA; Zav'ialova EG; Lapsheva EN; Babiĭ AV; Mudrik NN; Pavlova GV; Golovin AV; Kopylov AM
    Eksp Klin Farmakol; 2012; 75(11):13-8. PubMed ID: 23323327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
    Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH
    Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.